1: Home (ALT-H)
2: HMA Joint (ALT-M)
3: Human Medicines (ALT-U)
- 3.1: Heads of Agencies (ALT-E)
- 3.2: CMDh (ALT-C)
- 3.3: MRI Product Index (ALT-R)
- 3.4: Directory (ALT-I)
4: Veterinary Medicines (ALT-V)

You are here: Human Medicines > CMDh > Product Information > Core SmPC/PL

3.2.1: About CMDh (ALT-O)
3.2.2: Statistics (ALT-S)
3.2.3: Press Releases (ALT-P)
3.2.4: Procedural Guidance (ALT-L)
3.2.5: CMDh-Referrals
3.2.6: Product Information (ALT-T)
- 3.2.6.1: PhVWP Recommendations (ALT-W)
- 3.2.6.2: CMDh Recommendations (ALT-N)
- 3.2.6.3: Harmonisation of SmPCs - Article 30 Referrals (ALT-3)
- 3.2.6.4: Core SmPC/PL
3.2.7: Advice from CMDh
3.2.8: Templates
3.2.9: CMD Working Parties / Working Groups (ALT-K)
3.2.10: Paediatric Regulation (ALT-G)
3.2.11: Pharmacovigilance Legislation
3.2.12: Questions & Answers (ALT-Q)
3.2.13: Contact Form
3.2.14: Contact Points
3.2.15: What's new history (ALT-Y)

Core SmPC/PL

(see also Post referral Phase)

In order to view some of the documents on this website you need Acrobat Reader
(click here to download)

Fludeoxyglucose (18F) - Revised Core SmPC and PL (December 2010)

Hormone Replacement Therapy - Core SmPC (June 2012) [Track version]

Hormone Replacement Therapy - Core Package Leaflet (June 2012) [Track version]

Hormone Replacement Therapy - MRFG-PhVWP agreed updated core SmPC (October 2002)

Hormone Replacement Therapy - SmPC wording for medicinal products used in HRT with regard to increased risk of venous thromboembolism as agreed by the PhVWP (September 2001)

Hormone Replacement Therapy - SmPC wording for medicinal products used in HRT with regard to increased risk of breast cancer as agreed by the PhVWP (July 2001)

Trivalent influenza vaccines - Core SmPC (December 2011) [Track version]

Trivalent influenza vaccines - Core Package Leaflet (December 2011) [Track version]